Relative contribution of baseline variables in a nomogram to predict survival in patients treated with nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer

被引：0
|
作者：
David, Goldstein [1 ]
Daniel, Von Hoff [2 ]
Chiorean, E. [3 ]
Michele, Reni [4 ]
Josep, Tabernero [5 ]
Ramesh, Ramanathan [6 ]
Julia, Wilkerson [7 ]
Marc, Botteman [7 ]
Abdalla, Aly [7 ]
Sandra, Margunato-Debay [8 ]
Brian, Lu [8 ]
Chrystal, Louis [8 ]
Markus, Renschler [8 ]
Desmond, McGovern [9 ]
Chee, Lee [10 ]
机构：
[1] Prince Wales Hosp, Sydney, NSW, Australia
[2] TGen & HonorHlth, Phoenix, AZ USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Osped San Raffaele, Milan, Italy
[5] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[6] Scottsdale Healthcare TGen, Scottsdale, AZ USA
[7] Pharmerit Int, Bethesda, MD USA
[8] Celgene Corp, Summit, NJ USA
[9] Celgene, Stockley Pk, England
[10] Univ Sydney, NHMRC Clin Trial Ctr, Camperdown, Tyne & Wear, Scotland
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O - 017
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Erratum: Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
    E Gabriela Chiorean
    Daniel D Von Hoff
    Josep Tabernero
    Robert El-Maraghi
    Wen Wee Ma
    Michele Reni
    Marion Harris
    Robert Whorf
    Helen Liu
    Jack Shiansong Li
    Victoria Manax
    Alfredo Romano
    Brian Lu
    David Goldstein
    British Journal of Cancer, 2016, 115 : e13 - e13
  • [32] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Shuling Chen
    Jiaxin Li
    Aoran Dong
    Zelong Liu
    Meiyan Zhu
    Meng Jin
    Guangyan Wei
    Shuang Wu
    Yan Wang
    Yong Chen
    Zhenwei Peng
    Journal of Hematology & Oncology, 16
  • [33] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Chen, Shuling
    Li, Jiaxin
    Dong, Aoran
    Liu, Zelong
    Zhu, Meiyan
    Jin, Meng
    Wei, Guangyan
    Wu, Shuang
    Wang, Yan
    Chen, Yong
    Peng, Zhenwei
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [34] Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
    Angelica Petrillo
    Annalisa Pappalardo
    Luca Pompella
    Giuseppe Tirino
    Filomena Calabrese
    Maria Maddalena Laterza
    Marianna Caterino
    Anna Ventriglia
    Michele Orditura
    Giovanni Conzo
    Carlo Molino
    Fortunato Ciardiello
    Maria Biglietto
    Ferdinando De Vita
    Medical Oncology, 2019, 36
  • [35] Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
    Petrillo, Angelica
    Pappalardo, Annalisa
    Pompella, Luca
    Tirino, Giuseppe
    Calabrese, Filomena
    Laterza, Maria Maddalena
    Caterino, Marianna
    Ventriglia, Anna
    Orditura, Michele
    Conzo, Giovanni
    Molino, Carlo
    Ciardiello, Fortunato
    Biglietto, Maria
    De Vita, Ferdinando
    MEDICAL ONCOLOGY, 2019, 36 (10)
  • [36] Vitamin D receptor agonist paricalcitol plus gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer
    Perez, Kimberly
    Cleary, James M.
    Karasic, Thomas Benjamin
    Raghavan, Srivatsan
    Rahma, Osama E.
    Nowak, Jonathan
    Borazanci, Erkut Hasan
    Downes, Michael
    Drebin, Jeffrey A.
    Tuveson, David A.
    Ting, David Tsai
    Moffitt, Richard
    Yeh, Jen Jen
    Aguirre, Andrew
    Evans, Ronald
    Von Hoff, Daniel D.
    Odwyer, Peter J.
    Wolpin, Brian M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [37] Impact of nab-paclitaxel (nab-P) plus gemcitabine (G) vs gemcitabine alone on Karnofsky performance status (KPS) in metastatic pancreatic cancer.
    Chiorean, E. Gabriela
    Wan, Yin
    Whiting, Scott
    Kayitalire, Louis
    Botteman, Marc
    Ji, Xiang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer
    Kobayashi, Satoshi
    Suzuki, Motoko
    Ueno, Makoto
    Maruki, Yuta
    Okano, Naohiro
    Todaka, Akiko
    Ozaka, Masato
    Tsuji, Kunihiro
    Shioji, Kazuhiko
    Doi, Keitaro
    Kojima, Yasushi
    Tsumura, Hidetaka
    Tanaka, Kazunari
    Higuchi, Hajime
    Kawabe, Ken
    Imaoka, Hiroshi
    Yamashita, Tatsuya
    Miwa, Haruo
    Nagano, Hiroaki
    Arima, Shiho
    Hayashi, Hideyuki
    Naganuma, Atsushi
    Yamaguchi, Hironori
    Hisano, Terumasa
    Umemoto, Kumiko
    Ishii, Shuji
    Nakashima, Koji
    Suzuki, Rei
    Kitano, Yohei
    Misumi, Toshihiro
    Furuse, Junji
    Ishii, Hiroshi
    ONCOLOGIST, 2022, 27 (10): : E774 - E782
  • [39] Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer
    You, Min Su
    Ryu, Ji Kon
    Choi, Young Hoon
    Choi, Jin Ho
    Huh, Gunn
    Paik, Woo Hyun
    Lee, Sang Hyub
    Kim, Yong-Tae
    GUT AND LIVER, 2018, 12 (06) : 728 - 735
  • [40] The retrospective analysis of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer
    Ueno, M.
    Kobayashi, S.
    Ohkawa, S.
    Tezuka, S.
    Moriya, S.
    Morimoto, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 67 - 67
12345